The Current Drug Development Paradigm: Responding to US and European Demands for Evidence of Comparative Effectiveness and Relative Effectiveness
Published: Jan 1, 2014
Abstract
In the United States (US) and Europe, and indeed, globally, pharmaceutical companies are facing rapidly evolving regulatory and reimbursement evidentiary expectations linked in large part to the clinical and economic realities confronting their respective healthcare systems. Specifically, demands for comparative effectiveness research (CER) and relative effectiveness (RE) evidence have been driven by: (1) health care spending pressures; (2) lack...
Paper Details
Title
The Current Drug Development Paradigm: Responding to US and European Demands for Evidence of Comparative Effectiveness and Relative Effectiveness
Published Date
Jan 1, 2014
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History